Equities research analysts at StockNews.com started coverage on shares of Evoke Pharma (NASDAQ:EVOK – Get Free Report) in a report released on Saturday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Stock Up 5.5 %
NASDAQ EVOK opened at $0.53 on Friday. Evoke Pharma has a fifty-two week low of $0.40 and a fifty-two week high of $1.77. The stock has a market cap of $4.55 million, a price-to-earnings ratio of -0.29 and a beta of 0.36. The business has a fifty day moving average of $0.49 and a 200-day moving average of $0.66.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last announced its quarterly earnings data on Tuesday, May 14th. The specialty pharmaceutical company reported ($0.17) EPS for the quarter. Evoke Pharma had a negative net margin of 116.75% and a negative return on equity of 4,908.09%. The business had revenue of $1.74 million during the quarter.
About Evoke Pharma
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Featured Stories
- Five stocks we like better than Evoke Pharma
- How to Use Stock Screeners to Find Stocks
- Qualcomm Stock: AI-Powered Growth Despite Volatility
- What is Put Option Volume?
- Salesforce Stock: Meeting Recap, AI Focus, and Forecast
- The Role Economic Reports Play in a Successful Investment Strategy
- Is CAVA Overextended? A Closer Look at This High-Flying Stock
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
